Evaxion A/S (EVAX) stock
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.54−0.24 (-8.63%)
Close on Nov 18, 2026Market cap $21.18MP/E –Yield –
Evaxion A/S revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was $7.53M, up 125.1% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.53M | +125.1% |
| FY2024 | Dec 31, 2024 | $3.34M | +4480.8% |
| FY2023 | Dec 31, 2023 | $73.00K | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $37.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $154.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?